GC Corp. sells entire stake in Curevo held by subsidiary GC Biopharma to Eli Lilly for ~460 billion won... massive cash inflow to fund new business investments
GC Biopharma decided to sell all 21,075,336 shares of Curevo, Inc., a US vaccine developer, to global pharmaceutical company Eli Lilly and Company for approximately 459.9 billion won
The consideration consists of an upfront payment of 306.6 billion won and conditional milestone payments of 153.3 billion won; 284.7 billion won of the upfront is due within 6 business days upon closing conditions
The purpose is to secure funds for new business investments, with the expected disposal date of August 24, 2026, after which ownership will be zero
Curevo's total equity as of end-2025 was 86.9 billion won (not capital impairment), but it recorded a net loss of 63.3 billion won; the sale eliminates ongoing losses and brings substantial cash
The disposed asset represents 11.3% of the parent's consolidated total assets (approx. 4.07 trillion won); the cash proceeds are expected to be used for future growth investments
[AI Comprehensive Analysis]This stake sale monetizes a persistently loss-making asset at a premium, strongly positive for short-term financial improvement and funding for new businesses. However, milestone revenues are uncertain, and fully divesting a key pipeline may weaken long-term growth drivers.
KOSPI Filing Information
Filing: [Correction of Description] Decision on Disposal of Stocks and Equity Securities of Other Corporations (Major Management Matters of Subsidiary)